Bell Investment Advisors, Inc Novo Cure LTD Transaction History

Bell Investment Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $233 - $331	21 Added 140.0%	36 $0
Q3 2023 Nov 08, 2023	SELL	$16.15 - $42.35 $96 - $254	-6 Reduced 28.57%	15 $0
Q1 2023 May 10, 2023	SELL	$56.44 - $118.81 $846 - $1,782	-15 Reduced 41.67%	21 $1,000
Q2 2022 Aug 12, 2022	SELL	$56.6 - $89.9 $56 - $89	-1 Reduced 2.7%	36 $3,000
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $976 - $1,585	13 Added 54.17%	37 $3,000
Q3 2021 Nov 12, 2021	BUY	$116.17 - $194.55 $2,788 - $4,669	24 New	24 $3,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.79B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Bell Investment Advisors, Inc with notifications on news.